Skip to the page

Data / Drug companies / Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.: 10 products in the FDA NDC directory, labeler code 65897

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (labeler code 65897) lists 10 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 8 bulk ingredients, 2 prescription drugs. Its main marketing category is bulk ingredients. The newest product started marketing on October 8, 2025.

The request: Watch Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (FDA labeler code 65897): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
65897
Products in commercial distribution
10
Packages
15
Finished drugs by generic name
1
Prescription products
2
Over the counter products
0
Flagged as original packager
2 of 2 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
January 23, 2017
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients880%
Generic drugs (ANDA)220%

Products by type

TypeProductsShare
Bulk ingredients880%
Prescription drugs220%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Caspofungin acetate27

Dosage forms

Dosage formProductsShare
Powder880%
Injection, powder, lyophilized, for solution220%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Caspofungin acetate65897-0004Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)October 8, 2025
Caspofungin acetate65897-0002Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)August 26, 2025
Daptomycin65897-2011PowderBulk ingredientsDecember 9, 2022
Acarbose65897-4005PowderBulk ingredientsDecember 2, 2022
Tacrolimus65897-3010PowderBulk ingredientsJanuary 21, 2022
Mupirocin calcium65897-2007PowderBulk ingredientsJune 1, 2021
Polymyxin b sulfate65897-2004PowderBulk ingredientsJune 1, 2021
Mupirocin65897-2003PowderBulk ingredientsJune 1, 2021
Cyclosporine65897-3008PowderBulk ingredientsOctober 6, 2020
Tacrolimus65897-1010PowderBulk ingredientsJanuary 23, 2017

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.